Long PFS of more than 7  years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period

In conclusion, our study in an unselected patient group showed that 9% of patients with newly diagnosed myeloma experience prolonged PFS of more than 7 years in the era of conventional chemotherapy or first-generation novel agents. We anticipate that novel treatmen t approaches will increase the probability of achieving a prolonged relapse-free status.
Source: Annals of Hematology - Category: Hematology Source Type: research